COMP <GO>
KPRX vs UPC // FORWARD P/E MULTIPLE
Kiora Pharmaceuticals Inc. (NASDAQ) VS. Universe Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: KPRX 2
— UPC 1
■ METRIC PARITY
LAST: $1.76 (-25.42%) • MKT CAP: $7.8M
forward-pe
—
LAST: $1.54 (-20.21%) • MKT CAP: $7.7M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KPRX VS. UPC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KPRX | UPC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 35.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -16.30% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -20.60% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -22.40% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | UPC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.1 | 23.3 | +5.80 | KPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.8M | $7.7M | $49.4K | KPRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KPRX REV | UPC REV | KPRX GROSS % | UPC GROSS % | KPRX FCF | UPC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $17.86B | — | 35.3% | -$10.1M | -$5.32B |
| FY 2024 | $16.0M | $23.02B | — | 26.4% | $8.6M | -$9.72B |
| FY 2023 | $0 | $32.31B | — | — | -$9.6M | $1.12B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KPRX // BETA —
UPC // BETA —